A brain lesion as the sole metastasis of prostate cancer

Mithal, Prabhakar; Gong, Yuna; Sirkis, Hartley; Aronowitz, Jesse N.

doi:10.1177/2051415814549204

Cited by 6 publications

(5 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the low incidence of cerebral metastatic disease, cross-sectional neurological imaging is not routinely performed in prostate cancer patients and PET/CTs using PSMA-based radiopharmaceuticals are protocoled to cover the body from skull base to proximal thighs [4,5]. Twenty-one case reports of solitary brain metastases from prostate cancer were found in the literature, summarised in Table 1 [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21], adapted from Barakat et al (2016) [17].…”

Section: Introductionmentioning

confidence: 99%

Neurologically asymptomatic cerebral oligometastatic prostate carcinoma metastasis identified on [Ga]Ga-THP-PSMA PET/CT

et al. 2020

View full text Add to dashboard Cite

Background Brain metastases from prostate cancer are rare and usually only occur in the context of widespread systemic disease. This is the first case report of a solitary brain oligometastasis, in a neurologically intact prostate cancer patient with no other systemic disease, detected using [68Ga]Ga-THP-PSMA PET/CT and only the second one using a PSMA-based radiopharmaceutical. Case presentation We report the case of a prostate cancer patient presenting 5 years after robot-assisted laparoscopic prostatectomy with biochemical recurrence, no neurological symptoms, and in the absence of metastatic lesions in the body on conventional imaging. A solitary cerebral metastasis was detected using [68Ga]Ga-THP-PSMA PET/CT, surgically resected, leading to a drop in serum PSA and a good recovery. Conclusion In this case, [68Ga]Ga-THP-PSMA PET/CT resulted in a major change in clinical management and avoided additional morbidity associated with delayed diagnosis and treatment. This report demonstrates the importance of considering the presence of metastatic disease outside the conventional locations of prostate cancer spread, as well as the importance of ensuring comprehensive [68Ga]Ga-PSMA PET/CT coverage from vertex to upper thighs.

show abstract

Section: Introductionmentioning

confidence: 99%

Neurologically asymptomatic cerebral oligometastatic prostate carcinoma metastasis identified on [Ga]Ga-THP-PSMA PET/CT

et al. 2020

View full text Add to dashboard Cite

show abstract

“…In addition, the studied patients were high risk group with Gleason score ≥ 7. Despite, there are some published case reports indicated better prognosis with more than 2 years survival after treatment [21,22]. Simultaneously, our patient had low-risk prostate cancer who is doing well after 16 months since diagnosis and treatment of brain metastasis and rescinded hospice.…”

Section: Neurological Manifestations Of Brain Metastasismentioning

confidence: 66%

Untitled

2020

Int J Cancer Clin Res

View full text Add to dashboard Cite

Adenocarcinoma of prostate is the most common cancer affecting men in United States. The most common sites of prostate cancer metastasis are to bone and pelvic lymph nodes. Brain metastases are rare and reported in less than 1% of prostate cancer patients. Among the patients with brain metastasis, most of them had concurrent systemic disease involvement, such as: bone, lymph node, liver and/ or lung metastasis [1,2]. We report a case of patient with low risk prostate cancer, stage IV B, with well controlled systemic disease and developed brain metastasis.

show abstract

“…As the spectrum of progression widens in the prostate cancer tissue, the expression of the members of the Notch signal pathway have been found out to increase, too (20). Prostate cancer often metastasizes to the bone, lymph nodes, and the brain (21,22). Expression of the members of the Notch pathway is observed to increase in metastatic prostatic carcinoma cell lines.…”

Section: Molecular Changes In Prostate Carcinomamentioning

confidence: 99%

Prostat Karsinomunun Moleküler Yolakları

Bayramoğlu

Ünal

2020

Mustafa Kemal Üniversitesi Tıp Dergisi

View full text Add to dashboard Cite

Prostat kanseri, dünyada hızla artan insidans oranlarına sahip en yaygın kanser türlerinden biridir. Prostat kanseri insidansı ve mortalite oranları farklı popülasyonlarda büyük ölçüde değişkendir. Prostat kanseri, tümör baskılayıcı genlerin spesifik genom sekanslarında delesyon ve onkogen aktivasyonu ile ilişkili spesifik kromozomal bölgelerdeki değişiklikler gibi çoklu genetik modifikasyonları içerir. Prostat kanseri yol açan kalıtsal değişikliklerin bir veya daha fazla spesifik genetik özellik ile ilişkili olup olmadığını belirlemek zordur. Prostat karsinogenezi çok karmaşık olup hala mekanizmaları olarak açıklanmamıştır. Eğer prostat karsinogenezini daha iyi anlayabilirsek bu hastalar için hedefe yönelik tedavi de bulabiliriz. Bu nedenle biz burada prostat karsinomunda yer alan büyük genetik ve epigenetik değişikliklerden bahsetmek istedik.

show abstract

A brain lesion as the sole metastasis of prostate cancer

Cited by 6 publications

References 11 publications

Neurologically asymptomatic cerebral oligometastatic prostate carcinoma metastasis identified on [Ga]Ga-THP-PSMA PET/CT

Neurologically asymptomatic cerebral oligometastatic prostate carcinoma metastasis identified on [Ga]Ga-THP-PSMA PET/CT

Untitled

Prostat Karsinomunun Moleküler Yolakları

Contact Info

Product

Resources

About